Diagnostics of polycystic ovary syndrome

Česká verzia

Authors: Ivica Lazúrová; Jana Figurová; Zora Lazúrová
Authors place of work: I. interná klinika LF UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, DrSc., FRCP
Published in the journal: Vnitř Lék 2015; 61(Suppl 5): 40-44
Category: Reviews

Summary

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy among women of reproductive age and the most frequent cause of menstruation cycle disorders. It is marked by a hyperandrogenic state (clinical and/or biochemical) and ovulatory dysfunction (anovulation and/or ultrasonographic finding of polycystic ovaries), which are also criteria for its diagnosis according to Androgen Excess and PCOS Society. The syndrome has multiple phenotypic expressions, among them besides the above characteristics also a metabolic syndrome, primarily obesity and insulin resistance. Diagnosing of PCOS may be rather exacting in clinical practice and it remains to be a diagnosis per exclusionem, following elimination of other causes of hyperandrogenic state and chronic oligo-anovulation. It requires a close cooperation between a gynecologist and endocrinologist and with regard to frequent metabolic complications also with an internist, diabetologist and possibly cardiologist.

Key words:
AES criteria – diagnosis – differential diagnosis – polycystic ovary syndrome

Zdroje

1. March WA, Moor VM, Wilson KJ et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25(2): 544–551.

2. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol 2009 Fall; 2(4): 232–239.

3. Cussons AJ, Stuckey BG, Walsh JP et al. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) 2005; 62(3): 289–295.

4. Azziz R, Carmina E, Dewailly D et al. The Androgen Excess and PCOS Society criteria for polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91(2): 456–488.

5. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166(19): 2081–2086.

6. Yildiz BO, Bozdag G, Yapici Z et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27(10): 3067–3073.

7. Conway G, Dewailly D, Diamanti-Kandarakis E et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014; 171(1): 1–29.

8. Cibula D, Hill M, Starka L et al. The best correlation of the new index of hyperandrogenism with the grade of increased hair. Eur J Endocrinol 2000; 143(3): 405–408.

9. Yildiz BO, Boulour S, Woods K et al. Visually scoring hirsutism. Hum Reprod Update 2010; 16(1): 51–64.

10. Cibula D, Hill M, Vohradnikova O et al. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000; 143(2): 399–404.

11. Haciveliglou S, Gungor AN, Gencer M et al. Acne severity and the Global Acne Grading system in polycystic ovary syndrome. Int J Gynaecol Obstet 2013; 123(1): 33–36.

12. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89(6): 2745–2749.

13. Strowitzki T, Capp E, Von Eye Corleta H. The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. Eur J Gynecol Reprod Biol 2010; 149(2): 178–181.

14. Sanchez LA, Perez M, Centeno I et al. Determining the time androgens and sex hormone binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study. Fertil Steril 2007; 87(3): 712–714.

15. Dewailly D, Lujan ME, Carmina E et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20(3): 334–352.

16. Jonard S, Robert Y, Cortet-Rudelli C et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003; 18(3): 598–603.

17. Laven JS, Imani B, Eijkemans MJ et al. New approaches to PCOS and other forms of anovulatory infertility. Obstet Gynecol Surv 2002; 57(11): 755–767.

18. Homburg R, Crawford G. The role of AMH in anovulation associated with polycystic ovary syndrome: a hypothesis. Hum Reprod 2014; 29(6): 1117–1121.

19. Casadei L, Madrigale A, Puca F et al. The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 2013; 29(6): 545–550.

20. Livadas S, Diamanti-Kandarakis E. Polycystic ovary syndrome: Definition, Phenotypes and Diagnostic Approach. In: Macut D, Pfeifer M, Yildiz BO et al. Polycystic ovary syndrome. Novel Insights into Causes and Therapy: 40. Karger; Basel 2012: 1–21. ISBN 978–3318022384.